Working… Menu

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy (Nefigard)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03643965
Recruitment Status : Active, not recruiting
First Posted : August 23, 2018
Last Update Posted : August 2, 2021
Information provided by (Responsible Party):
Calliditas Therapeutics AB